Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis

Durvalumab is approved for the treatment of lung cancer, advanced biliary tract cancers, and is also being evaluated in many other solid organ tumors. The aim of our study is to define the incidence, etiology, and outcomes of liver injury in consecutive patients receiving durvalumab-based immunother...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2022-10, Vol.12, p.984940
Main Authors: Swanson, Linnea A, Kassab, Ihab, Tsung, Irene, Schneider, Bryan J, Fontana, Robert J
Format: Article
Language:English
Subjects:
checkpoint inhibitors
drug hepatotoxicity
drug induced liver injury
immune-mediated liver injury
immunotherapy
Oncology
Roussel Uclaf Causality Assessment Method
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Durvalumab is approved for the treatment of lung cancer, advanced biliary tract cancers, and is also being evaluated in many other solid organ tumors. The aim of our study is to define the incidence, etiology, and outcomes of liver injury in consecutive patients receiving durvalumab-based immunotherapy. Durvalumab treated patients between 1/2016 - 7/2020 were identified from the electronic medical record. Liver injury was defined as serum AST or ALT ≥ 5x upper limit of normal (ULN), ALP ≥ 2x ULN, bilirubin ≥ 2.5 mg/dl, or INR ≥ 1.5. Potential drug induced liver injury (DILI) cases were adjudicated using expert opinion scoring and confirmed with Roussel Uclaf Causality Assessment Method (RUCAM). Amongst 112 patients, 58 (52%) had non-small cell lung cancer, the median age was 65 years, and 60% were male. The 21 (19%) liver injury patients were significantly more likely to harbor hepatic metastases (52% vs 17%, p=
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.984940